Table 3.

Hazard Ratio for Overall Survival & Sensitivity Analysis (2nd line ipilimumab vs historical controls)

		Hazard Ratio (95% CI)	P-value
Primary Analyses	Model A: Unadjusted Model	0.65 (0.52–0.82)	0.0003
	Model B: IPTW Weighted Model	0.62 (0.52–0.73)	< 0.0001
Sensitivity Analyses	Model C: IPTW Weighted Model adjusting for 3rd line	0.64 (0.53–0.76)	< 0.0001
	Model D: IPTW Weighted Model adjusting for 3rd line checkpoint inhibitor treatment
	2nd line Ipilimumab	0.63 (0.53–0.75)	< 0.0001
	Historical Controls	Ref
	Model E: Censoring patients at start of 3rd line		< 0.0001
	2nd line Ipilimumab	0.60 (0.48–0.73)
	Historical Controls	Ref
	Model F: Excluding patients who started 3rd line treatment		0.0001
	2nd line Ipilimumab (n = 122)	0.67 (0.55–0.81)
	Historical Controls (n = 102)	Ref